Digital therapeutics are rapidly coming into the foreground to treat a variety of conditions. Ben…
One of the greatest commodities in the healthcare industry is the provision of medically relevant…
This post was originally published on Source Link
Bristol Myers Squibb has announced positive topline results from its phase 3 trial of Reblozyl…
Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive…
Nicox has had both good and bad news from a much-anticipated phase 3 trial of…
Eli Lilly’s links to Purdue University go back a long way, and have been reinvigorated…
- Pharma News
Specialty pharma’s next big opportunity: it’s time for patient access to adopt an open protocol
In January 2020, the financial conglomerate Visa announced it was acquiring a relatively unknown startup,…
Between the 2nd and 4th November, a veritable who’s who of British industry will gather…
Verge Genomics has joined a select group of biotechs who have taken a drug discovered…
Shares in French biotech Inventiva were on the slide this morning after AbbVie revealed that…
The Galien Foundation, which acknowledges “extraordinary scientific innovations that improve the human condition”, has awarded…
Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML)…
When Michael Sen took over as chief executive of Fresenius at the start of this…
Forecasting is essential in providing clarity on decision making about the future, but poor-quality forecasts…
Shares in US biotech Y-mAbs Therapeutics have lost almost a third of their value after…
In June, NHSE and NICE published details on the Innovative Medicines Fund, which will help…
The EMA has delivered some good news to GSK on a new long-acting HIV drug…
Boehringer Ingelheim was an early adopter of Medidata’s electronic data collection (EDC) platform for clinical…
During Reuters Pharma 2022, in Nice, France, pharmaphorum web editor Nicole Raleigh briefly spoke to…
Gilead Sciences has been knocked back in its quest to bring the first drug therapy…
The sooner a human-centred perspective is applied to the development of either a drug or…
Alnylam has said it will not proceed with a clinical trial of its RNAi drug…
Santhera has completed a rolling application for its Duchenne muscular dystrophy (DMD) therapy vamorolone in…
The concept of patient centricity has been a key talking point across the healthcare ecosystem…
Last month, pharmaphorum had the chance to speak with Dr Isabelle Ray-Coquard, professor of medical…
The FDA has accepted for review Seres Therapeutics’ Biologics License Application (BLA) for SER-109, an…
A bot that provide support to relatives of people with cancer – called Scally –…
In this special, live edition of the pharmaphorum podcast, recorded at the conclusion of Frontiers…
GSK has said it will not be able to move ahead with regulatory filings for…
On 28 September 2022, the international and European self-regulatory bodies for the research-based pharmaceutical industry…
To proceed please enable Javascript (and Cookies) in your browser. Generic ViagraSildenafil Citrate 25/50/100/120/130/150/200mg Generic…
Drugmakers Pfizer and Flynn Pharma have formally launched an appeal against a £70 million ($84…
When people think about pharma, they often think about “big” pharma: large, faceless corporations. But…
AstraZeneca seems to have dodged the problems besetting other developers of oral selective estrogen receptor…
Biotech start-up Normunity, Inc. has exited stealth with a $65 million Series A to create…
German specialty drugmaker Neuraxpharm has licensed commercial rights in Europe to a wearable device developed…
Johnson & Johnson has secured another regulatory approval for its BCMAxCD3 bispecific antibody for multiple…
Less than a week before Ipsen’s palovarotene was due to go in front of an…
Psoriasis is a tricky disease to manage, as drawbacks and side effects loom with each…
Healthware, as the key R&D partner, has been supporting Orion Corporation to design and develop…
The healthcare company Syncona Limited has announced its newly established portfolio company is to acquire…
Astellas has been having some safety-related issues with its gene therapy programmes of late, but…
AstraZeneca’s IL-5 inhibitor Fasenra is already making blockbuster sales from its use in eosinophilic asthma,…
Novartis has abandoned development of its drug to treat presbyopia, a common age-related loss of…
The time of healthcare professionals is limited, but systems often rely on them as the…
A sweetened offer from Sumitomo Pharma has convinced endocrinology specialist Myovant to agree to a…
Novartis has chalked up another clinical trial win for its targeted factor B inhibitor iptacopan…
Psychedelic medicines company Beckley Psytech has reached an agreement to acquire its rival Eleusis Therapeutics,…
AstraZeneca’s lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a…